Latest Regulatory Milestones News

Ballard Mining’s September quarter report highlights promising drilling results at its Mt Ida Gold Project and secures final approvals for a 2.0 Mtpa processing plant, underpinning its development ambitions.

Imagion Biosystems has made significant strides toward filing an IND application for its MagSense® HER2 breast cancer imaging agent, supported by positive FDA feedback and a recent $3.5 million capital raise to fund upcoming clinical trials.

BPH Global Ltd reports a steady increase in Indonesian seaweed sales alongside securing a crucial export licence, setting the stage for international market entry.

Southern Palladium has raised A$20 million through a strategic share placement to accelerate its Bengwenyama PGM project, positioning the company for key milestones including a Final Investment Decision in 2026.

Neuren Pharmaceuticals has secured FDA Fast Track designation for its drug NNZ-2591 targeting Phelan-McDermid syndrome, accelerating its path through clinical development. This milestone underscores the urgent need for treatments in rare neurodevelopmental disorders.

Orthocell has boosted its investment in Marine Biomedical to secure exclusive global distribution rights for PearlBone™, an innovative bone substitute nearing FDA approval, enhancing its regenerative medicine portfolio.

Structural Monitoring Systems (ASX – SMN) reports a robust third consecutive profitable quarter, driven by soaring avionics sales and a landmark US defense contract via Canada’s CCC program. Revenue climbs 23% year-on-year, signaling strong momentum in its Special Mission communications business.

PainChek Limited has confirmed FDA De Novo classification for its PainChek Adult App, promptly disclosing the material regulatory milestone to the ASX and signalling a significant step towards US market entry.

Ark Mines has secured Environmental Authority approval for its Sandy Mitchell Rare Earths project in Queensland, marking a crucial step towards obtaining its Mining Licence. The company has also completed a major drilling program, setting the stage for an upcoming Pre-Feasibility Study.

Firebrick Pharma has secured a $102,000 investment from its Philippines strategic partner, Pharma Nutria N.A., Inc., reinforcing its position ahead of the Nasodine nasal spray launch in 2026.

Toubani Resources has achieved a crucial regulatory milestone with the Environmental and Social Impact Assessment approval for its Kobada Gold Project in Mali, paving the way for on-site development activities.

Anteris Technologies has secured its first European regulatory clearance to commence the global PARADIGM Trial for its DurAVR Transcatheter Heart Valve, marking a significant step toward worldwide commercialization.